Prior to LFN treatment, RA patients exhibited high disease activity indexes (DAS28-ESR and SDAI), and increased pain and disability paralleled to elevated C-reactive protein and rheumatoid factor levels. This evidence concerns the gene CRP and rheumatoid arthritis.